Market Research in Oman

Physician surveys, payer and access qual, stakeholder mapping, and executive synthesis aligned to MOH tender and formulary behaviour.

Muscat concentration versus interior referral patterns requires segmented design so forecasts reflect real patient flows.

Yes. Harmonised GCC modules preserve Oman-specific MOH context while enabling regional portfolio reads.

Programs map Royal Hospital, SQUH, and relevant private groups depending on therapy and access objective.

See the pharmaceutical companies in Oman page linked below for BOFU company-intent research.

This directorate governs drug registration, pharmacovigilance, and pricing approval in Oman, and its timelines can move independently of Saudi SFDA or UAE MOHAP processes even for the same molecule. Research programmes track Oman-specific registration status separately rather than assuming Gulf-wide approval implies local listing readiness, since a molecule registered elsewhere in the Gulf may still be pending locally.

Specialist care outside Muscat is often delivered through regional referral hospitals with smaller teams and longer patient catchment areas, which means recruitment in the interior typically takes longer per completed interview than in the capital. We build this into field timelines rather than applying a flat national recruitment rate that assumes Muscat-level responsiveness everywhere.

Yes, where access can be arranged and is appropriate to the study scope. These tertiary referral centres treat a disproportionate share of complex and specialty cases nationally, so they are often the right starting point for oncology, rare disease, or advanced therapy research even when the broader study also covers regional facilities, and their specialists are frequently the most credible voices for advisory-style qualitative work.

Oman's public spending constraints have historically made price and budget-impact evidence more central to formulary decisions than in wealthier neighbouring markets, and that sensitivity has increased further as the government has pursued fiscal diversification under its Vision 2040 economic plan. Research programmes should expect budget-holder objections to carry real weight rather than treating them as a formality.

Yes, where the therapy area and decision warrant it. Salalah and other regional hubs sit between Muscat tertiary care and the smallest interior towns in terms of specialist density, so we scope them as a distinct field cell rather than lumping them in with either extreme, which keeps regional readiness assessments realistic and defensible when presented to leadership.

We typically run a short round of pilot outreach — two or three specialists per relevant region — to confirm realistic recruitment numbers before finalizing sample size and budget. This catches scarcity issues early rather than mid-field, when a redesign becomes far more expensive and can delay the entire delivery timeline.

Yes. The same underlying stakeholder map and instrument design can be adapted for an initial launch-readiness study and later reused, with updates, for an access defense against a new competitor or a formulary re-review, which keeps findings comparable over time and reduces both the cost and turnaround time of the second engagement considerably.